Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its intention to conduct a public offering of its common stock and warrants to purchase shares of common stock. The offering is expected to raise approximately $10 million in gross proceeds, which will be utilized to fund research and development activities, including the planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, as well as for general corporate purposes. The offering will consist of 6,666,667 shares of common stock and accompanying Series G and Series H warrants, with a combined offering price of $1.50 per share. The Series G warrants will be exercisable immediately and will expire in five years, while the Series H warrants will also be exercisable immediately but will expire in one year. The offering is subject to market conditions and is expected to close on or about March 20, 2026, pending customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. This capital raise is seen as a strategic move to bolster the company's financial position and support its ongoing clinical trials, which are critical for its growth and development in the competitive pharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.